Pharming provides update on outstanding shares
(Thomson Reuters ONE) -
Leiden, The Netherlands, June 29, 2010. Biotech company Pharming Group NV
("Pharming") (NYSE Euronext: PHARM) today announced that its current number of
outstanding shares has increased from 285,691,836 at June 18, 2010 to
304,953,323 as per today.
The increase reflects an aggregate number of 7,661,250 shares in relation to
conversions of bonds and 11,600,237 shares in relation to the exercise of
warrants issued upon entering into ?7.5 million private bonds in January 2010.
As a result, the original nominal value of the bonds issued in the amount of
?7.5 million has decreased to ?1.1 million today.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of genetic
disorders, ageing diseases, specialty products for surgical indications, and
nutritional products. On June 24, the European Medicines Agency adopted a
positive opinion for Ruconest(Rhucin)for the treatment of angioedema attacks.
Market Authorization in the European Economic Area is therefore expected to be
granted in September 2010. The product is also under development for follow-on
indications, i.e. antibody-mediated rejection (AMR) and delayed graft function
(DGF) following kidney transplantation. Prodarsan® - a product under development
by Pharming's subsidiary DNage - is in early stage clinical development for
Cockayne Syndrome and lactoferrin for use in food products. The advanced
technologies of the Company include innovative platforms for the production of
protein therapeutics, technology and processes for the purification and
formulation of these products, as well as technology in the field of DNA repair
(via DNage). Recently the partial spin off of DNage was initiated. Additional
information is available on the Pharming website, http://www.pharming.com.
This press release contains forward looking statements that involve known and
unknown risks, uncertainties and other factors, which may cause the actual
results, performance or achievements of the Company to be materially different
from the results, performance or achievements expressed or implied by these
forward looking statements.
Contact:
Ms. Marjolein van Helmond, T: +31 (0)71 52 47 431 or +31 (0)6 109 299 54
[HUG#1428369]
Press release (PDF): http://hugin.info/132866/R/1428369/375751.pdf
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Pharming Group N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 29.06.2010 - 19:30 Uhr
Sprache: Deutsch
News-ID 23201
Anzahl Zeichen: 0
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Pharming provides update on outstanding shares"
steht unter der journalistisch-redaktionellen Verantwortung von
Pharming Group N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
